2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-126551
    Butenoyl-PAF 474944-25-7 98%
    Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.
    Butenoyl-PAF
  • HY-126718
    Methylenecyclopropylpyruvate 5746-24-7 98%
    Methylenecyclopropylpyruvate (Ketohypoglycin) is an inhibitor for gluconeogenesis. Methylenecyclopropylpyruvate inhibits ketogenesis and affects the fatty acids metabolism. Methylenecyclopropylpyruvate may interfere with the mitochondrial β-oxidation pathway, affects the contents and composition of coenzyme A, and affects the glucose homeostasis.
    Methylenecyclopropylpyruvate
  • HY-126734
    Avenanthramide E 93755-77-2 98%
    Avenanthramide E is a collagen synthesis inhibitor. Avenanthramide E inhibits TGF-β-stimulated Collagen synthesis. Avenanthramide E can be used for the research of diabetic nephropathy.
    Avenanthramide E
  • HY-126751
    DBM-819 331686-58-9 98%
    DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase (H+/K+-ATPase), with an IC50 value of 5 μM. DBM-819 can reversibly block gastric acid secretion by inhibiting the proton pump in the gastric mucosa. It shows significant protective effects against duodenal ulcers induced by Cysteamine (HY-77591), gastric ulcers induced by Indomethacin (HY-14397), and gastric ulcers induced by Aspirin (HY-14654), with EC50 values of 6, 3.1, and 4 mg/kg respectively. DBM-819 can be used in ulcer prevention research.
    DBM-819
  • HY-126756
    Amorphin 4207-90-3 98%
    Amorphin is a phosphorylase b with glycogen metabolism activity. Amorphin binds directly to alpha-actinin, with alpha-actinin mediating its binding to actin filaments. Amorphin can be used for the research of McArdle’s disease and breast cancer.
    Amorphin
  • HY-126807
    AS1907417 885038-66-4 98%
    AS1907417 is a novel GPR119 agonist with an oral activity. AS1907417 is a modified form of AS1269574. AS1907417 has antihyperglycemic and can be used in the research of type 2 diabetes.
    AS1907417
  • HY-126825
    NE21650 427899-21-6 98%
    NE21650 potently inhibits farnesyl diphosphate (FPP) synthase. NE21650 is a weak inhibitor of isopentenyl diphosphate (IPP) isomerase. NE21650 is a potent inhibitor of protein prenylation in osteoclasts and macrophages and bone resorption in vitro.
    NE21650
  • HY-126845
    3-cis-Hydroxyglibenclamide 23074-02-4 98%
    3-cis-Hydroxyglibenclamide is the metabolism of Glibenclamid (HY-15206).
    3-cis-Hydroxyglibenclamide
  • HY-126852
    4-Hydroxy Atorvastatin lactone 163217-70-7 98%
    4-Hydroxy Atorvastatin lactone is a metabolite of Atorvastatin (HY-B0589). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.
    4-Hydroxy Atorvastatin lactone
  • HY-12689A
    Mitapivat hemisulfate sesquihydrate 2151847-10-6 98%
    Mitapivat hemisulfate sesquihydrate (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency.
    Mitapivat hemisulfate sesquihydrate
  • HY-12689B
    Mitapivat hemisulfate 2329710-91-8 98%
    Mitapivat hemisulfate is an orally active pyruvate kinase allosteric activator. Mitapivat hemisulfate increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat hemisulfate can be used in study of PK deficiency.
    Mitapivat hemisulfate
  • HY-12689C
    Mitapivat hydrochloride 2559738-69-9 98%
    Mitapivat (AG-348) hydrochloride is an orally active and selective allosteric pyruvate kinase R (PK-R) activator. Mitapivat hydrochloride accelerates the reaction of PK-R catalyzing the conversion of phosphoenolpyruvate to pyruvate, thereby promoting the glycolytic pathway, increasing the production of adenosine triphosphate (ATP) in red blood cells, and reducing the level of 2,3-diphosphoglycerate (2,3-DPG). Mitapivat hydrochloride is promising for research of pyruvate kinase deficiency and other anemia-related diseases.
    Mitapivat hydrochloride
  • HY-12689S
    Mitapivat-d8
    Mitapivat-d8 (AG-348-d8) is the deuterium labeled Mitapivat (HY-12689). Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency.
    Mitapivat-d8
  • HY-126904
    ZINC08792355 904513-52-6 98%
    ZINC08792355 is a SIRT1 inhibitor and can be used for study of ageing, diabetes, and cancer..
    ZINC08792355
  • HY-126907
    A32390A 61241-59-6 98%
    A32390A is a dopamine β-hydroxylase inhibitor and copper chelator. A32390A can inhibit the synthesis of norepinephrine, which helps lower blood pressure in DOCA hypertensive rats. A32390A can be used in research on hypertension, bacterial infections, and metabolic disorders.
    A32390A
  • HY-126910
    Mesyl Salvinorin B 862073-79-8 98%
    Mesyl Salvinorin B is a potent and selective kappa opioid receptor (KOP-r) agonist. Mesyl Salvinorin B prevents the ADE (Alcohol deprivation effect) in mice. Mesyl Salvinorin B dose-dependently reduces alcohol intake and preference in CED (chronic escalation drinking) mice.
    Mesyl Salvinorin B
  • HY-126912
    Lauroyl coenzyme A 6244-92-4 98%
    Lauroyl coenzyme A (Dodecanoyl coenzyme A) is an ester product.
    Lauroyl coenzyme A
  • HY-126923
    2,3-Dinor thromboxane B2 63250-09-9 98%
    2,3-Dinor thromboxane B2 (2,3-Dinor-TXB2), a metabolite of urine, serves as an indicator of the production of thromboxane A2 (TxA2) in the body, and can be used as a tool to study the role of thromboxane in various pathophysiological processes in the human body.
    2,3-Dinor thromboxane B2
  • HY-126955
    Ethylmalonyl-CoA 6049-57-6 98%
    Ethylmalonyl-CoA (Ethylmalonyl coenzyme A) is a coenzyme A derivative.
    Ethylmalonyl-CoA
  • HY-126956
    Porphyra 334 70579-26-9 98%
    Porphyra 334 is a carnosine-like amino acid and a natural photoprotective agent and antioxidant. Porphyra-334 exerts its photoprotective effects by scavenging ROS, inhibiting the expression and activity of MMP-1/8, and promoting the synthesis of collagen and elastin. Porphyra 334 effectively inhibits linoleic acid oxidation induced by alkyl radicals (AAPH) and singlet oxygen. Porphyra 334 has anti-obesity potential by inhibiting the expression of PPARγ2 and C/EBPα. Porphyra 334 protects cells against UV-induced DNA damage and apoptosis by inhibiting the activation of caspase-3.
    Porphyra 334
Cat. No. Product Name / Synonyms Application Reactivity